Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common antifungal keep Crohn's away after surgery?

NCT ID NCT02997059

Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the antifungal drug fluconazole could lower levels of certain antibodies (ASCA) and prevent Crohn's disease from returning after bowel surgery. Thirty-five adults with Crohn's disease who had recent ileal or ileocecal resection were randomly assigned to receive fluconazole or a placebo for six months. The goal was to see if targeting a yeast in the gut could reduce inflammation and recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

35 people

The number who actually took part.

Start date

Jul 2008

Finished

Jun 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Crohn disease patients with a small intestine localisation (ileum or ileocecal) 2. Ileal or ileocecal resection in the month before inclusion (resection of all macroscopic lesions). If resection with temporary stoma, the patient may be included at the time of surgery to restore the continuity 3. Patient with low risk of recurrence according to the following criteria: (i) Total length of the resection(s) of the small intestine less than 100 cm (ii) Segmental colectomy leaving in place at least another colonic segment as the rectum 4. Preoperative rate of ASCA\> 70 arbitrary units (+/- 10%) 5. Informed consent signed to be involved in the study Exclusion Criteria: 1. Pregnant women or without adequate contraception 2. Total length of the resection(s) of the small intestine more than 1 meter 3. Subtotal colic resection 4. Preoperative rate of ASCA\<63 arbitrary units (+/- 10%) 5. Known hypersensitivity to fluconazole or other azoles 6. Known liver disease or transaminase levels \>1.5 the normal rate 7. Patient with renal failure 8. Inability to read and sign the informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn's disease aggravated are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease Torulopsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn's disease aggravated

Contacts and locations

Locations

  • CHRU, Hôpital Claude Huriez

    Lille, France